# Sun Pharma: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Sun Pharmaceutical Industries Limited · NSE: SUNPHARMA · BSE: 524715 · Sector: Healthcare

Updated for Q2 FY27 · checked 11 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/sun-pharma. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Sun Pharma: how the business works", with the page URL.

## In short

Buyers in more than 100 countries, including India and the US, pay Sun Pharma for its medicines; most of the money goes on research, marketing, staff and materials, and ₹19 of every ₹100 was left as profit in FY26.

- In FY26 India gave 33.8% of Sun Pharma's sales, the US 30.3%, emerging markets 20.1% and the rest of the world 15.8%.
- Of every ₹100 that came in during FY26, ₹29.4 went on running costs such as research and marketing, ₹19.1 on materials and ₹18.9 on staff.

## Key facts

**What does Sun Pharma do?**

Sun Pharmaceutical Industries Ltd (Sun Pharma) makes and sells medicines in more than 100 countries, including India and the US. Sun Pharma's corporate office is in Mumbai and its registered office in Vadodara. Its FY26 revenue from operations was ₹58,462 crore. [S1, S2, S9]

**How does Sun Pharma make money?**

Sun Pharma sells branded medicines in India, generic (off-patent) medicines in the US and other countries, and patented innovative medicines such as Ilumya. In FY26 Sun Pharma's innovative medicines sold US$1,420 million, 20.7% of its sales excluding a milestone payment. [S18, S2]

**Who are Sun Pharma's customers?**

In FY26 Sun Pharma's sales came 33.8% from India, 30.3% from the US, 20.1% from emerging markets and 15.8% from the rest of the world. No single customer gave Sun Pharma 10% or more of its FY26 revenue. [S1]

**How big is Sun Pharma?**

Sun Pharma's FY26 revenue was ₹58,462 crore and its profit for shareholders was ₹11,479 crore. Its FY26 EBITDA (profit before interest, tax, depreciation and amortisation) was ₹16,424 crore. Sun Pharma reports 40 manufacturing plants and more than 47,000 employees in the group. [S1, S2, S27]

**Who owns Sun Pharma?**

On 30 Sep 2026 Sun Pharma's promoter group, the Shanghvi family and its companies, held 52.68% of the shares. Foreign investors held 14.36%, Indian institutions 22.27% and other shareholders 10.70%. The promoter share fell from 54.48% in Jun 2026 because the Valia family was reclassified as public shareholders; no shares were sold. [S39, S38, S47]

**What is Sun Pharma's share of the Indian medicine market?**

Sun Pharma had an 8.5% share of India's medicine market in the 12 months to Jun 2026, with ₹21,538 crore of sales, according to AIOCD data quoted in Sun Pharma's Sep 2026 investor presentation. [S27]

**How much debt does Sun Pharma have?**

On 30 Sep 2026 Sun Pharma had borrowings of ₹2,694 crore and cash and liquid investments of ₹33,570 crore. Sun Pharma then allotted ₹7,816 crore of non-convertible debentures (bonds) on 26 Oct 2026. [S9, S56]

**How did Sun Pharma do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Sun Pharma's revenue rose 11.9% to ₹16,199 crore. Sun Pharma's profit for shareholders fell 36.2% to ₹1,989 crore, after ₹1,269 crore of one-off charges. [S9]

**Has Sun Pharma completed its purchase of Organon?**

No. Sun Pharma agreed on 27 Apr 2026 to buy Organon & Co. for US$14 a share in cash, and the deal had not closed as of Sun Pharma's 30 Oct 2026 earnings call. [S45, S12]

**What dividend does Sun Pharma pay?**

Sun Pharma's dividend for FY26 was ₹16 per share (₹11 interim and ₹5 final), equal to 33.5% of its FY26 earnings per share of ₹47.8. [S3, S1]

## What does Sun Pharma sell?

Sun Pharma makes medicines. Most are generics: versions of drugs whose patents have expired. In India it sells them under its own brand names, which doctors prescribe. It also sells its own patented 'innovative' medicines, mainly for skin, eye and cancer conditions.

- **Branded medicines in India:** Medicines sold under Sun Pharma's own brands and prescribed by doctors: ₹19,290 crore of sales in FY26. In AIOCD market data for the 12 months to Jun 2026, nervous-system and mental-health medicines were 19% of its India sales and heart medicines 17%. [S18, S27]
- **Generic medicines in the US:** Lower-priced versions of off-patent drugs. Sun Pharma says it is the 13th largest generics company in the US (IQVIA, 12 months to Jun 2026). It had 561 approved and 120 pending US generic drug applications on 30 Sep 2026. [S27, S10]
- **Innovative (patented) medicines:** Its own patented drugs, such as Ilumya (psoriasis), Cequa (dry eye), Winlevi (acne), Leqselvi (hair loss from alopecia areata) and Unloxcyt (a skin cancer). Sales were US$1,420 million in FY26, 20.7% of total sales excluding a milestone payment. [S18, S2]
- **Medicines in emerging markets and other countries:** Generic and branded medicines sold outside India and the US: ₹11,187 crore of formulation sales in emerging markets and ₹8,568 crore in the rest of the world in FY26. [S18]
- **Drug ingredients (API):** Active pharmaceutical ingredients, the substance in a medicine that does the work, sold to other companies: ₹2,185 crore in FY26. [S18]

## Who pays Sun Pharma?

- **Buyers in India (33.8% of revenue):** Medicines sold in India, mostly under Sun Pharma's brands. Its sales team of over 16,000 people visits doctors. Share is of FY26 sales; drug-ingredient sales are counted in the region where they were sold. [S1, S27]
- **Buyers in the US (30.3% of revenue):** Generic and innovative medicines sold in the US. US formulation sales were US$1,904 million in FY26. [S1, S18]
- **Buyers in emerging markets (20.1% of revenue):** Medicines sold in emerging markets. Formulation sales there were US$1,265 million in FY26, up 13%. [S1, S18]
- **Buyers in the rest of the world (15.8% of revenue):** Medicines sold in other countries. Formulation sales there were US$969 million in FY26, up 14%. [S1, S18]
- **Customer concentration:** No single customer gave Sun Pharma 10% or more of revenue in any year from FY22 to FY26, according to its segment note. The documents collected do not say how much its largest US buyers take. [S1]

## Where the money went (FY26)

1. In FY26 Sun Pharma's medicines brought in ₹58,462 crore of revenue, plus ₹1,972 crore of other income.
2. Materials took ₹11,544 crore and employees ₹11,419 crore.
3. Other running costs, such as research and marketing, took ₹17,768 crore, after a ₹1,240 crore currency gain.
4. One-off charges took ₹1,308 crore and income tax ₹3,554 crore.
5. What was left for Sun Pharma's shareholders was ₹11,479 crore of profit.

Sources: S1, S9.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 38,655 | 5,831 | 15.1% | 3,273 | 8.5% | 13.6 | 8,985 | 1,495 | 7,490 | S7 |
| FY23 | 43,886 | 11,475 | 26.1% | 8,474 | 19.3% | 35.3 | 4,959 | 2,086 | 2,874 | S6 |
| FY24 | 48,497 | 12,529 | 25.8% | 9,576 | 19.7% | 39.9 | 12,135 | 2,202 | 9,933 | S5 |
| FY25 | 52,578 | 14,594 | 27.8% | 10,929 | 20.8% | 45.6 | 14,072 | 2,129 | 11,944 | S1 |
| FY26 | 58,462 | 16,424 | 28.1% | 11,479 | 19.6% | 47.8 | 12,419 | 3,609 | 8,810 | S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Sun Pharma's cash and liquid investments were ₹30,877 crore more than its borrowings, before it raised ₹7,816 crore through bonds in Oct 2026. [S9, S1, S56, S40, S11, S44]

| Item | Value |
| --- | --- |
| Total debt | 2,694 |
| Cash and investments | 33,570 |
| Net debt (debt minus cash) | −30,877 |
| Net worth (shareholders' money) | 89,280 |
| Debt to equity (times) | 0.03 |

- Borrowings exclude lease liabilities (rent owed under leases) of ₹548 crore.
- Cash and liquid investments = cash, other bank balances and current investments. Net worth is the equity belonging to Sun Pharma's shareholders.
- On 26 Oct 2026 Sun Pharma allotted ₹7,816 crore of non-convertible debentures (bonds). They are not in the 30 Sep 2026 figures.
- CRISIL said on 13 Oct 2026 that the Organon purchase would be funded with US$2.0–2.5 billion of cash and US$9.5–10.0 billion of debt, including about US$8.5 billion of Organon's own debt taken over.
- Sun Pharma's own measure of net cash, on its own definition, was US$3.3 billion on 30 Sep 2026.
- Moody's rated Sun Pharma Baa1 (Stable) and S&P BBB+ (Stable) on 8 Sep 2026, its first international ratings.
- On 31 Mar 2026 the group was disputing ₹711 crore of income-tax claims, and tax authorities had appealed ₹6,440 crore of orders that went in its favour.

## Who owns Sun Pharma? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 52.68% |
| Promoter shares pledged (% of promoter shares) | 0.01% |
| Foreign institutions (FII) | 14.36% |
| Indian institutions (DII) | 22.27% |
| Public | 10.7% |

Sources: S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S38, S39, S46, S47.

## What could go wrong

### US FDA and quality checks at plants

Four Indian plants carry US FDA findings, and Halol has been on an import alert since Dec 2022. In Aug 2026 Sun Pharma recalled 11 eye-care products from its Assam plant and paused production there. [S1, S51, S12, S40]

What to watch: New FDA inspection results for Halol, Mohali, Dadra and Baska, and the restart of the Assam plant.

### Organon purchase and new debt

The Organon purchase has not closed. CRISIL says it will be funded with US$2.0–2.5 billion of cash and US$9.5–10.0 billion of debt. Sun Pharma's borrowings were ₹2,694 crore on 30 Sep 2026. Organon deal costs were ₹513 crore in H1 FY27, and Sun Pharma expects more. [S40, S9, S12]

What to watch: Completion of the deal (management expects Q4 FY27) and borrowings in the first balance sheet after it.

### Falling US generic sales

US formulation sales fell 8.2% in US dollars in Q2 FY27, to US$455 million; management said this was largely due to lower lenalidomide sales. CRISIL notes price pressure in US generics from authorised generics, buyer consolidation and other Indian makers. [S10, S12, S40]

What to watch: US formulation sales in US dollars each quarter.

### US lawsuits and settlements

One-off charges for US legal settlements recur: ₹3,723 crore in FY22, US$200 million in FY26 and ₹923 crore in Q2 FY27, all settled without admitting wrongdoing. In Aug 2026 a US appeals court ruled for Sun Pharma in the Lipitor antitrust case. [S7, S9, S53, S55]

What to watch: Further charges in the US generic-drug pricing antitrust case.

### US drug pricing and tariffs

Management said on 30 Oct 2026 that it agreed with the US government to offer most-favoured-nation (MFN) prices to state Medicaid programmes, and that this delays Section 232 tariffs on its innovative products for over 2 years. CRISIL lists US tariffs and MFN pricing as risks. [S12, S40]

What to watch: Changes to US drug-pricing and tariff rules, and US innovative-medicine sales.

### Small promoter pledge

On 30 Sep 2026, 85,000 promoter-group shares held by Kumud Shantilal Shanghvi were pledged, 0.01% of the promoter holding. Pledged shares are given as loan collateral; a lender can sell them if a loan is not repaid. [S39, S38]

What to watch: Pledged share of the promoter holding in each quarterly shareholding filing.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Organon deal completion:** Management said on 30 Oct 2026 that it expects to complete the purchase in Q4 FY27 (Jan–Mar 2027). The first balance sheet after it will show the new debt.
- **US sales:** US formulation sales fell 8.2% in US dollars in Q2 FY27, to US$455 million. Management said on 30 Oct 2026 that Ilumya for psoriatic arthritis would have a soft US launch in November, then a full launch in the following months.
- **Plant inspections:** Any new US FDA result for Halol, Mohali, Dadra or Baska, and whether production restarts at the Assam eye-care plant.

## Sources

- S1: Annual Report FY26: Consolidated Financial Statements section. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/07/Consolidated-Financial-Results.pdf (published 6 Jul 2026)
- S2: Annual Report FY26: Chairman/MD message and Management Discussion & Analysis section. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/07/Chairman-MDs-Message-and-Management-Discussion-Analysis.pdf (published 6 Jul 2026)
- S3: Annual Report FY26: Board's Report and Corporate Governance section. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/07/Boards-Report-and-Corporate-Governance.pdf (published 6 Jul 2026)
- S4: Business Responsibility and Sustainability Report FY26 (standalone). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/07/Business-Responsibility-and-Sustainability-Report.pdf (published 6 Jul 2026)
- S5: Annual Report FY25: Consolidated Financial Statements section. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2025/07/Consolidated-Financial-Results.pdf (published 4 Jul 2025)
- S6: Annual Report FY24: Consolidated Financial Statements section. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2024/07/SPIL-AR2023-24-Consolidated-Financial-Results.pdf (published 8 Jul 2024)
- S7: Annual Report FY23: Consolidated Financial Statements section. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2023/07/SPIL-AR2022-23-Consolidated-Financial-Results.pdf (published 27 Jul 2023)
- S9: Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/10/SPIL-Q2FY26-Financial-Results.pdf (published 30 Oct 2026)
- S10: Press release: Sun Pharma reports Q2FY27 results. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/10/Press-Release-Sun-Pharma-Q2FY27-Financial-Result.pdf (published 30 Oct 2026)
- S11: Q2 FY27 earnings presentation. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/10/Sun-Pharma_Q2FY27-Earnings-Presentation.pdf (published 30 Oct 2026)
- S12: Q2 FY27 earnings call transcript (call 30 Oct 2026). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/11/FY27-Q2-Earnings-Call-Transcript.pdf (published 4 Nov 2026)
- S13: Unaudited consolidated financial results Q1 FY27 (quarter ended 30 Jun 2026). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/07/Q1FY27-SPIL-Financial-Results.pdf (published 31 Jul 2026)
- S17: Audited consolidated financial results Q4 FY26 and FY26. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/05/SPIL-Q4FY26-Financial-Results.pdf (published 22 May 2026)
- S18: Press release: Sun Pharma reports Q4FY26 and FY26 results. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/05/Press-Release-Sun-Pharma-Q4FY26-Financial-Result.pdf (published 22 May 2026)
- S19: Q4 FY26 earnings call transcript (call 22 May 2026). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/06/FY26-Q4-Earnings-Call-Transcript.pdf (published 29 May 2026)
- S20: Unaudited consolidated financial results Q3 FY26 (quarter ended 31 Dec 2025). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/01/SPIL-Q3FY26-Financial-Results.pdf (published 31 Jan 2026)
- S25: Press release: Sun Pharma reports Q4FY23 and FY23 results. Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2023/05/Press-Release-Sun-Pharma-Q4FY23-Financial-Result-1.pdf (published 26 May 2023)
- S26: Q4 FY25 earnings call transcript (call 22 May 2025). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2025/05/FY25-Q4-Earnings-Call-Transcript.pdf (published 29 May 2025)
- S27: Investor presentation, September 2026 ("Creating Lasting Value"). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/09/SPIL-IR-Presentation-Sept-2026-INR-1.pdf (published 22 Sep 2026)
- S28: Shareholding pattern as of 31 Dec 2023 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_184298_1022316_16012024124452_WEB.xml (published 16 Jan 2024)
- S29: Shareholding pattern as of 31 Mar 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_187414_1097458_18042024115146_WEB.xml (published 18 Apr 2024)
- S30: Shareholding pattern as of 30 Jun 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_190201_1193503_19072024115758_WEB.xml (published 19 Jul 2024)
- S31: Shareholding pattern as of 30 Sep 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_192385_1273313_16102024070115_WEB.xml (published 16 Oct 2024)
- S32: Shareholding pattern as of 31 Dec 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_195742_1353889_20012025075522_WEB.xml (published 20 Jan 2025)
- S33: Shareholding pattern as of 31 Mar 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_197857_1417896_17042025075818_WEB.xml (published 17 Apr 2025)
- S34: Shareholding pattern as of 30 Jun 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1489053_21072025051303_WEB.xml (published 21 Jul 2025)
- S35: Shareholding pattern as of 30 Sep 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1549859_16102025124943_WEB.xml (published 16 Oct 2025)
- S36: Shareholding pattern as of 31 Dec 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1601600_15012026043651_WEB.xml (published 15 Jan 2026)
- S37: Shareholding pattern as of 31 Mar 2026 (NSE XBRL, revised filing). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1682212_17062026123958_WEB.xml (published 17 Jun 2026)
- S38: Shareholding pattern as of 30 Jun 2026 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1694893_17072026122439_WEB.xml (published 17 Jul 2026)
- S39: Shareholding pattern as of 30 Sep 2026 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1738462_15102026105915_WEB.xml (published 15 Oct 2026)
- S40: Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale. Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_13102026175414_Intimation_to_SE_-_NCDs_Credit_Ratings.pdf (published 13 Oct 2026)
- S44: Intimation: international credit ratings (Moody's Baa1, S&P BBB+). Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_08092026203827_SEIntimationforInternationalCreditRatings.pdf (published 8 Sep 2026)
- S45: Intimation and press release: definitive agreement to acquire Organon & Co.. Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_27042026052308_SEIntimationOrganon27042026.pdf (published 27 Apr 2026)
- S46: Intimation: receipt of requests for reclassification from promoter group to public (Valia family). Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_14052026122407_SEIntimation_Receipt_of_Reclassification_Request.pdf (published 14 May 2026)
- S47: Intimation: shareholders approve reclassification from promoter group to public. Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_26092026221702_SEintimationforoutcomeofreclassification.pdf (published 26 Sep 2026)
- S48: Board outcome: appointment of Deloitte Haskins & Sells as statutory auditors (mandatory rotation). Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_30102026151827_BMOutcome30102026_Conclusion.pdf (published 30 Oct 2026)
- S50: Intimation: approval of ₹3,000 crore greenfield formulations facility in Madhya Pradesh. Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNPHARMA123_02122025230649_Intimation.pdf (published 2 Dec 2025)
- S51: Intimation: US FDA classifies Baska facility inspection as OAI. Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_18122025082632_SEIntimationforOAIstatus.pdf (published 18 Dec 2025)
- S52: Clarification on news report about the Assam facility. Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_02112026205719_Reply_to_SEs_-_Rumour_Verification02112026.pdf (published 2 Nov 2026)
- S53: Intimation: settlement agreement with a plaintiff in the generic drug pricing antitrust litigation (US). Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_11092026195640_SEIntimationGxMDLSept2026.pdf (published 11 Sep 2026)
- S54: Board outcome 12 Oct 2026: NCD issue up to ₹10,000 crore approved; independent director Gautam Doshi resigns. Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_12102026200413_BMOutcome12October2026.pdf (published 12 Oct 2026)
- S55: Intimation: update on Lipitor antitrust litigation (US appeals court affirms judgment for the company). Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_17082026083921_SEIntimationforupdateonLipitor.pdf (published 17 Aug 2026)
- S56: Intimation: allotment of non-convertible debentures of ₹7,816 crore. Sun Pharmaceutical Industries Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SUNSEC_26102026122925_SE_Intimation_of_allotment_of_NCDs_26_Oct_2026.pdf (published 26 Oct 2026)
- S57: NSE capital market bhavcopy, 11 Nov 2026 (SUNPHARMA EQ close). National Stock Exchange of India. https://nsearchives.nseindia.com/content/cm/BhavCopy_NSE_CM_0_0_0_20261111_F_0000.csv.zip (published 11 Nov 2026)
